Open AccessDevelopment of the Commercial Manufacturing Process for Ipatasertib
Author(s) -
Stephan Bachmann,
Hans Iding,
Christian Lautz,
Isabelle Thomé-Pfeiffer,
Caroline Maierhofer,
Régis Mondière,
Philipp Schmidt,
Christoph E. Strasser,
Thomas Bär,
André Aebi,
Andreas Schuster
Publication year - 2021
Publication title -
chimia
Language(s) - English
Resource type - Journals
eISSN - 2673-2424
pISSN - 0009-4293
DOI - 10.2533/chimia.2021.605
Subject(s) - stereocenter , prostate cancer , drug development , process (computing) , combinatorial chemistry , computer science , drug , computational biology , cancer , nanotechnology , chemistry , catalysis , medicine , materials science , pharmacology , biology , biochemistry , operating system , enantioselective synthesis
Ipatasertib is a potent small molecule Akt kinase inhibitor currently tested in Phase III clinical trials for the treatment of metastatic castration-resistant prostate cancer and triple negative metastatic breast cancer. In this paper an overview of the development achievements towards the commercial manufacturing process is given. The convergent synthesis consists of ten steps with eight isolated intermediates and utilizes a wide range of chemical techniques and technologies to build-up this complex drug. All three stereocenters are introduced using enzyme or metal catalysis.